BioRestorative Therapies, Inc.
BRTX
$1.09
$0.010.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 383.40K | 605.20K | 391.00K | 401.00K | 377.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 383.40K | 605.20K | 391.00K | 401.00K | 377.00K |
| Cost of Revenue | 25.50K | 33.10K | 30.90K | 28.00K | 24.70K |
| Gross Profit | 357.90K | 572.10K | 360.10K | 373.00K | 352.30K |
| SG&A Expenses | 6.68M | 6.61M | 6.33M | 6.30M | 7.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.90M | 13.70M | 12.64M | 11.96M | 12.46M |
| Operating Income | -14.51M | -13.09M | -12.25M | -11.56M | -12.09M |
| Income Before Tax | -12.67M | -10.72M | -12.10M | -8.98M | -9.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.67 | -10.72 | -12.10 | -8.98 | -9.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.67M | -10.72M | -12.10M | -8.98M | -9.65M |
| EBIT | -14.51M | -13.09M | -12.25M | -11.56M | -12.09M |
| EBITDA | -14.30M | -12.89M | -12.06M | -11.37M | -11.90M |
| EPS Basic | -1.48 | -1.28 | -1.47 | -1.17 | -1.46 |
| Normalized Basic EPS | -0.79 | -0.67 | -0.79 | -0.60 | -0.91 |
| EPS Diluted | -1.48 | -1.28 | -1.47 | -1.17 | -1.46 |
| Normalized Diluted EPS | -0.79 | -0.67 | -0.79 | -0.60 | -0.91 |
| Average Basic Shares Outstanding | 34.34M | 33.34M | 32.73M | 31.04M | 27.60M |
| Average Diluted Shares Outstanding | 34.34M | 33.34M | 32.73M | 31.04M | 27.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |